BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30952657)

  • 1. Tissue-Specific Oncogenic Activity of KRAS
    Poulin EJ; Bera AK; Lu J; Lin YJ; Strasser SD; Paulo JA; Huang TQ; Morales C; Yan W; Cook J; Nowak JA; Brubaker DK; Joughin BA; Johnson CW; DeStefanis RA; Ghazi PC; Gondi S; Wales TE; Iacob RE; Bogdanova L; Gierut JJ; Li Y; Engen JR; Perez-Mancera PA; Braun BS; Gygi SP; Lauffenburger DA; Westover KD; Haigis KM
    Cancer Discov; 2019 Jun; 9(6):738-755. PubMed ID: 30952657
    [No Abstract]   [Full Text] [Related]  

  • 2. KRAS Alleles: The Devil Is in the Detail.
    Haigis KM
    Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.
    Le Roux Ö; Pershing NLK; Kaltenbrun E; Newman NJ; Everitt JI; Baldelli E; Pierobon M; Petricoin EF; Counter CM
    Elife; 2022 Sep; 11():. PubMed ID: 36069770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
    Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
    Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An
    Zafra MP; Parsons MJ; Kim J; Alonso-Curbelo D; Goswami S; Schatoff EM; Han T; Katti A; Fernandez MTC; Wilkinson JE; Piskounova E; Dow LE
    Cancer Discov; 2020 Nov; 10(11):1654-1671. PubMed ID: 32792368
    [No Abstract]   [Full Text] [Related]  

  • 6. Structural basis of the atypical activation mechanism of KRAS
    Bera AK; Lu J; Wales TE; Gondi S; Gurbani D; Nelson A; Engen JR; Westover KD
    J Biol Chem; 2019 Sep; 294(38):13964-13972. PubMed ID: 31341022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific.
    Cook JH; Melloni GEM; Gulhan DC; Park PJ; Haigis KM
    Nat Commun; 2021 Mar; 12(1):1808. PubMed ID: 33753749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAS Mutations Are Not Created Equal.
    Hobbs GA; Der CJ
    Cancer Discov; 2019 Jun; 9(6):696-698. PubMed ID: 31160330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
    Johnson CW; Lin YJ; Reid D; Parker J; Pavlopoulos S; Dischinger P; Graveel C; Aguirre AJ; Steensma M; Haigis KM; Mattos C
    Cell Rep; 2019 Aug; 28(6):1538-1550.e7. PubMed ID: 31390567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models.
    Puliga E; De Bellis C; Vietti Michelina S; Capeloa T; Migliore C; Orrù C; Baiocchi GL; De Manzoni G; Pietrantonio F; Reddavid R; Fumagalli Romario U; Ambrogio C; Corso S; Giordano S
    Gastric Cancer; 2024 May; 27(3):473-483. PubMed ID: 38261067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical KRAS
    Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
    Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
    Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
    Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.
    Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA
    Mol Cancer Res; 2012 Jun; 10(6):845-55. PubMed ID: 22532587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey.
    Park JT; Johnson N; Liu S; Levesque M; Wang YJ; Ho H; Huso D; Maitra A; Parsons MJ; Prescott JD; Leach SD
    Oncogene; 2015 May; 34(21):2801-6. PubMed ID: 25065594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular epidemiology and diagnostics of KRAS mutations in human cancer.
    Timar J; Kashofer K
    Cancer Metastasis Rev; 2020 Dec; 39(4):1029-1038. PubMed ID: 32725342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
    Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
    Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.
    Liu Z; Liu Y; Qian L; Jiang S; Gai X; Ye S; Chen Y; Wang X; Zhai L; Xu J; Pu C; Li J; He F; Huang M; Tan M
    Mol Cell; 2021 Oct; 81(19):4076-4090.e8. PubMed ID: 34375582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.
    Yin G; Kistler S; George SD; Kuhlmann N; Garvey L; Huynh M; Bagni RK; Lammers M; Der CJ; Campbell SL
    J Biol Chem; 2017 Mar; 292(11):4446-4456. PubMed ID: 28154176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation-Specific and Common Phosphotyrosine Signatures of
    Tahir R; Renuse S; Udainiya S; Madugundu AK; Cutler JA; Nirujogi RS; Na CH; Xu Y; Wu X; Pandey A
    J Proteome Res; 2021 Jan; 20(1):670-683. PubMed ID: 32986951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.